Hyperkalemia

There are 133 papers on hyperkalemia in aging research: 21 trials and 35 observational studies in people, 1 in animals, 65 reviews.

Disease

133 papers study it19 more mention it45 findings

MeSH

58 new papers in 30 daysSee all 152 papers on hyperkalemia

At a glance

Hyperkalemia is linked with in-hospital mortality in people with acute decompensated heart failure and cardiovascular mortality in people receiving maintenance hemodialysis. Human trials report increased hyperkalemia with finerenone and potassium-enriched salt substitutes; a trial reports less spironolactone-associated hyperkalemia with added dapagliflozin on background irbesartan therapy.

45 findings in 41 papers from 2016 to 2026, 27 of them since May 2026

“salt substitute increased mean serum potassium and led to more frequent biochemical hyperkalemia”
Salt substitution and salt-supply restriction for lowering blood pressure in elderly care facilities: a cluster-randomized trialNature medicine2023doi:10.1038/s41591-023-02286-8
  • Human trial21
  • Humans35
  • Animals1
  • In silico2

Interventions

11

Finerenone

upin humans2RR 2.03

2 studies
  1. Finerenone increases hyperkalemia in humans (RR 2.03, 95% CI 1.82–2.26).

    “Finerenone increased hyperkalaemia (RR 2.03, 95% CI: 1.82-2.26)”

    Human trial

    Comparative Cardiorenal Efficacy and Safety of Finerenone, SGLT2 Inhibitors, Semaglutide and Their Combination in Diabetic Kidney Disease

    Diabetes, obesity & metabolism

  2. Finerenone increases hyperkalemia in humans (Chronic kidney disease with type 2 diabetes).

    “Finerenone increased hyperkalemia without increasing acute kidney injury.”

    ReviewChronic kidney disease with type 2 diabetes

    Comparative Cardiorenal Efficacy and Safety of SGLT2 Inhibitors and Finerenone in Chronic Kidney Disease With Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

    Diabetes, obesity & metabolism

More on Finerenone

Dietary potassium intake

no changein humans1

1 study
  1. Dietary potassium intake was not clearly linked with hyperkalemia in humans (maintenance hemodialysis patients).

    “Dietary potassium intake was not associated with serum potassium levels or hyperkalaemia risk”

    Humansmaintenance hemodialysis patients

    Dietary potassium intake from different food sources and mortality in maintenance haemodialysis patients: a multicentre prospective cohort study

    The British journal of nutrition

More on Dietary potassium intake

Baxdrostat

upin humans1

1 study
  1. Baxdrostat increases hyperkalemia in humans (resistant or uncontrolled hypertension; compared with placebo) (2.6% with baxdrostat versus 0.4% with placebo).

    “Hyperkalemia (serum K + >6.0 mmol/L) occurred in 2.6% of baxdrostat-treated patients versus 0.4% with placebo.”

    Reviewresistant or uncontrolled hypertension; compared with placebo

    Nocturnal Blood Pressure Reduction with Baxdrostat: A Targeted Literature Review and Meta-Analysis

    AHA Scientific Sessions 2026 abstract

More on Baxdrostat

Potassium-enriched salt substitutes

upin humans1RR 2.1

1 study
  1. Potassium-enriched salt substitutes increase hyperkalemia in humans (RR 2.10 (95% CI 1.35-3.26)).

    “whilst biochemical hyperkalaemia events increased significantly (RR 2.10; 95% CI 1.35-3.26; I2=0%)”

    Human trial75% NaCl / 25% KCl formulationn = 24,998

    Perioperative empagliflozin and risk of acute kidney injury after cardiac surgery: a systematic review and meta-analysis

    ESC Congress 2026 abstract

More on Potassium-enriched salt substitutes

Eplerenone

no changein humans1

1 study
  1. Eplerenone showed no clear effect on hyperkalemia in humans (Obesity and essential hypertension; compared with irbesartan-based treatment) (1.2% versus 1.3% (p=1.00)).

    “Hyperkalemia (≥5.5 mmol/L) was rare and occurred in 1.2% and 1.3% of patients, respectively (p=1.00), with no treatment discontinuations.”

    Human trialObesity and essential hypertension; compared with irbesartan-based treatment25 mg twice daily6 monthsn = 162

    Renal function and hyperkalemia with first-line eplerenone in obese patients with hypertension: randomized safety data from the HEBRO trial

    ESC Congress 2026 abstract

More on Eplerenone

Amiloride

upin mice1

1 study
  1. Amiloride increases hyperkalemia in KLhet mice.

    “Pharmacological ENaC inhibition with amiloride precipitated severe hyperkalemia in KLhet mice.”

    Animalsin KLhet mice

    Klotho deficiency disrupts potassium balance in mice

    Acta physiologica (Oxford, England)

More on Amiloride

Rapamycin

downin mice1

1 study
  1. Rapamycin decreases hyperkalemia in KLhet mice.

    “treatment with the mTORC1 inhibitor rapamycin or Klotho supplementation suppressed renal mTORC1 signaling, restored plasma membrane ROMK1 abundance, increased urinary potassium excretion, and normalized serum potassium levels”

    Animalsin KLhet micekidney

    Klotho deficiency disrupts potassium balance in mice

    Acta physiologica (Oxford, England)

More on Rapamycin

Finerenone + SGLT2 inhibitors

upin humans1RR 2.48

1 study
  1. Finerenone + SGLT2 inhibitors increase hyperkalemia in humans (finerenone combined with empagliflozin, compared with empagliflozin alone) (RR 2.48, 95% CI 1.22–5.06).

    “Finerenone plus empagliflozin was associated with a higher risk of hyperkalaemia than empagliflozin alone (RR 2.48, 95% CI: 1.22-5.06)”

    Human trialfinerenone combined with empagliflozin, compared with empagliflozin alone

    Comparative Cardiorenal Efficacy and Safety of Finerenone, SGLT2 Inhibitors, Semaglutide and Their Combination in Diabetic Kidney Disease

    Diabetes, obesity & metabolism

More on Finerenone + SGLT2 inhibitors

SGLT2 inhibitors

no changein humans1

1 study
  1. SGLT2 inhibitors were not clearly linked with hyperkalemia in humans.

    “Hyperkalemia was associated with lower eGFR, but not with SGLT2i treatment”

    Humans

    SGLT2 inhibitors in kidney transplant recipients: metabolic changes, potassium-related safety and implications for albuminuria assessment

    Frontiers in transplantation

More on SGLT2 inhibitors

Dapagliflozin + spironolactone

downin humans1

1 study
  1. Dapagliflozin + spironolactone decreases hyperkalemia in humans (on irbesartan background therapy; relative to spironolactone-associated hyperkalemia).

    “while attenuating the risk of spironolactone-associated hyperkalemia”

    Human trialon irbesartan background therapy; relative to spironolactone-associated hyperkalemia72 weeks

    Effect of dapagliflozin-spironolactone combination therapy versus monotherapy on albuminuria reduction and hyperkalemia risk in elderly patients with early type 2 diabetic nephropathy receiving high-dose RASi: A randomized controlled trial

    The American journal of the medical sciences

More on Dapagliflozin + spironolactone

All 11

Upstream

1

Klotho

downin mice1

1 study
  1. Klotho decreases hyperkalemia in KLhet mice.

    “treatment with the mTORC1 inhibitor rapamycin or Klotho supplementation suppressed renal mTORC1 signaling, restored plasma membrane ROMK1 abundance, increased urinary potassium excretion, and normalized serum potassium levels”

    Animalsin KLhet micesupplementationkidney

    Klotho deficiency disrupts potassium balance in mice

    Acta physiologica (Oxford, England)

More on Klotho

Associations

18

Baxdrostat

upin humans8downin humans1OR 5.14–5.98

9 studies
  1. Baxdrostat raises the risk of hyperkalemia in humans (resistant hypertension).

    “A confirmed potassium level of more than 6 mmol/L occurred in three (3%) of the 108 baxdrostat recipients and in none of the placebo recipients.”

    Human trialresistant hypertension2 mg orally once daily12 weeksn = 217

    Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial

    Lancet (London, England)

  2. Baxdrostat raises the risk of hyperkalemia in humans (hypertension; compared with placebo) (8.9% vs. 1.2%; OR 5.98).

    “Safety analysis showed higher odds of hyperkalemia (8.9% vs. 1.2%; OR 5.98; P = 0.008)”

    Reviewhypertension; compared with placebo

    Baxdrostat in Resistant and Uncontrolled Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    AHA Scientific Sessions 2026 abstract

  3. Baxdrostat raises the risk of hyperkalemia in humans (hypertension; potassium ≥6.0 mmol/L) (OR 5.14 (95% CI 1.76–14.97)).

    “The pooled odds ratio for potassium ≥6.0 mmol/L was 5.14 (95% CI: 1.76 to 14.97).”

    Reviewhypertension; potassium ≥6.0 mmol/L

    Efficacy and Safety of Baxdrostat for Hypertension: A Systematic Review and Meta-Analysis of Three Phase 2/3 Randomized Controlled Trials

    AHA Scientific Sessions 2026 abstract

  4. Baxdrostat raises the risk of hyperkalemia in humans (resistant or uncontrolled hypertension; compared with placebo) (RR 4.39; 95% CI 2.05–9.40).

    “Baxdrostat increased hyperkalemia (RR 4.39; 95% CI 2.05-9.40; p=0.002)”

    Reviewresistant or uncontrolled hypertension; compared with placebo

    Blood Pressure-Lowering Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension: A Systematic Review, Meta-Analysis, and Dose-Response Analysis with Trial Sequential Analysis

    AHA Scientific Sessions 2026 abstract

  5. Baxdrostat lowers the risk of hyperkalemia in humans (resistant hypertension; compared with spironolactone) (Hyperkalemia (>6.0 mEq/L): baxdrostat 2 mg 3.0%, spironolactone 9.6% (95% CI 1.6-40.6)).

    “demonstrates comparable blood pressure reduction to spironolactone in resistant hypertension but with a significantly lower risk of hyperkalemia.”

    Reviewresistant hypertension; compared with spironolactone

    Comparative Efficacy and Safety of Aldosterone Synthase Inhibitors versus Mineralocorticoid Receptor Antagonists for Resistant Hypertension: A Systematic Review and Network Meta-Analysis

    AHA Scientific Sessions 2026 abstract

  6. Baxdrostat raises the risk of hyperkalemia in humans (resistant hypertension; compared with placebo) (RR 3.77 (95% CI 2.29–6.21); 103 events with baxdrostat versus 19 with placebo).

    “Hyperkalemia risk was increased (risk ratio [RR] 3.77 ; 95% CI 2.29-6.21;”

    Reviewresistant hypertension; compared with placebon = 1,996

    Baxdrostat for Resistant Hypertension: A Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials

    AHA Scientific Sessions 2026 abstract

  7. Baxdrostat raises the risk of hyperkalemia in humans (uncontrolled and resistant hypertension; compared with placebo) (RR 5.35; 95% CI 1.76, 16.25; NNH 19).

    “There was, however, a significant increase in the incidence of hyperkalemia (RR 5.35; 95% CI 1.76, 16.25; NNH 19; I2 = 0)”

    Reviewuncontrolled and resistant hypertension; compared with placebon = 1,729

    Baxdrostat for treatment of uncontrolled and resistant hypertension: a meta-analysis and systematic review

    ESC Congress 2026 abstract

  8. Baxdrostat raises the risk of hyperkalemia in humans (resistant hypertension) (RR 2.87, 95% CI 1.61-5.11).

    “baxdrostat increased hyperkalemia risk (serum potassium ≥5.5 mmol/L) (RR: 2.87; 95% CI: 1.61-5.11; moderate certainty)”

    Reviewresistant hypertension

    Efficacy and Safety of Baxdrostat in Resistant Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    Cureus

  9. Baxdrostat raises the risk of hyperkalemia in humans (resistant hypertension).

    “Baxdrostat and Lorundrostat were associated with significant increases in serum potassium levels and hyperkalemia.”

    Reviewresistant hypertension

    Aldosterone synthase inhibitors for resistant or uncontrolled hypertension: a network meta-analysis of randomized clinical trials

    Journal of hypertension

More on Baxdrostat

Aldosterone synthase inhibitors

upin humans4RR 4.43–8.97

4 studies
  1. Aldosterone synthase inhibitors raise the risk of hyperkalemia in humans (uncontrolled or resistant hypertension; compared with placebo) (RR 8.97).

    “Regarding safety, ASIs significantly increased hyperkalemia (RR 8.97)”

    Reviewuncontrolled or resistant hypertension; compared with placebo

    Clinical Outcomes of Novel Aldosterone Synthase Inhibitors (Lorundrostat and Baxdrostat) in Low and High Dose in Uncontrolled Hypertension: A Systematic Review and Meta-Analysis of RCTs

    AHA Scientific Sessions 2026 abstract

  2. Aldosterone synthase inhibitors raise the risk of hyperkalemia in humans (uncontrolled or resistant hypertension; compared with placebo) (OR 4.93, 95% CI 1.99–12.20).

    “ASIs significantly increased hyperkalemia, hypotension, and treatment discontinuation without increasing serious adverse events.”

    Reviewuncontrolled or resistant hypertension; compared with placebo

    Aldosterone Synthase Inhibitors in Adequate Blood Pressure Control in Uncontrolled/Resistant Hypertension: A Meta-Analysis of Randomized Controlled Trials

    AHA Scientific Sessions 2026 abstract

  3. Aldosterone synthase inhibitors raise the risk of hyperkalemia in humans (hypertension) (RR 4.43, 95% CI 2.40–8.19).

    “Hyperkalemia was more common with treatment (RR 4.43, 95% CI 2.40-8.19)”

    Reviewhypertension

    Antihypertensive Efficacy and Safety of Aldosterone Synthase (CYP11B2) Inhibitors: A GRADE-Guided Systematic Review and Meta-Analysis with Trial Sequential Analysis

    AHA Scientific Sessions 2026 abstract

  4. Aldosterone synthase inhibitors raise the risk of hyperkalemia in humans (RR 5.04).

    “Safety signals included reduced eGFR (MD -6.91 mL/min/1.73 m2), hyperkalemia [risk ratio (RR) 5.04], hyponatremia (RR 2.11), and symptomatic hypotension (RR 3.17)”

    Review

    Efficacy and Safety of Selective Aldosterone Synthase Inhibitors in Uncontrolled Hypertension: A Systematic Review and Dose-Specific Network Meta-Analysis of Randomized Controlled Trials

    Cardiology in review

More on Aldosterone synthase inhibitors

Finerenone

upin humans3downin humans1HR 1.35–1.47

4 studies
  1. Finerenone raises the risk of hyperkalemia in humans (CKD and T2D; irrespective of initiation strategy).

    “Rates of hyperkalemia were higher with finerenone”

    Human trialCKD and T2D; irrespective of initiation strategy180 days

    Simultaneous versus sequential initiation of CKM therapies: an indirect comparison of CONFIDENCE and FIDELITY

    ESC Congress 2026 abstract

  2. Finerenone is associated with hyperkalemia in humans (Patients with chronic kidney disease and type 2 diabetes; compared with nonusers) (HR 1.47, 95% CI 1.31–1.65).

    “Finerenone initiators were more likely to experience hyperkalemia (HR, 1.47; 95% CI, 1.31-1.65).”

    HumansPatients with chronic kidney disease and type 2 diabetes; compared with nonusersmale, 53%s

    Real-world effectiveness and safety of finerenone in patients with chronic kidney disease and type 2 diabetes in the United States: A FOUNTAIN platform analysis

    ESC Congress 2026 abstract

  3. Finerenone is linked with a lower risk of hyperkalemia in humans (CKD and non-DM patients versus steroidal MRAs).

    “a significantly reduced risk of hyperkalemia in CKD and non-DM patients”

    HumansCKD and non-DM patients versus steroidal MRAs

    Comparative effectiveness of mineralocorticoid receptor antagonists in cardiovascular, renal and metabolic disease

    Current problems in cardiology

  4. Finerenone is associated with hyperkalemia in humans (HR 1.35; 95% CI 1.11–1.69; risk-based analyses were not statistically significant).

    “Hyperkalemia occurred more often with finerenone (HR 1.35; 95% CI: 1.11 to 1.69) although risk-based analyses did not reach statistical significance.”

    HumansChronic kidney disease and type 2 diabetes; finerenone added to SGLT2 inhibitor therapy versus SGLT2 inhibitor monotherapy1 year

    Additive Cardiorenal Benefits of Finerenone and SGLT2 Inhibitor Combination Therapy in Diabetic CKD: A Propensity-Matched Real-World Study

    The American journal of cardiology

More on Finerenone

Cardiovascular mortality

upin humans1

1 study
  1. Hyperkalemia predicts cardiovascular mortality in humans (maintenance hemodialysis patients; serum potassium ≥6.0 mmol/L) (aHR 1.59, 95% CI 1.06–2.38).

    “severe hyperkalaemia (serum potassium ≥6·0 mmol/L) independently predicted cardiovascular mortality (aHR: 1·59, 95% CI: 1·06–2·38)”

    Humansmaintenance hemodialysis patients; serum potassium ≥6.0 mmol/L

    Dietary potassium intake from different food sources and mortality in maintenance haemodialysis patients: a multicentre prospective cohort study

    The British journal of nutrition

Hepatic angiotensinogen-lowering RNA therapeutics

upin humans1RR 2.8

1 study
  1. Hepatic angiotensinogen-lowering RNA therapeutics raise the risk of hyperkalemia in humans (hypertension; versus control) (RR 2.80; 95% CI 1.30 to 6.04).

    “Hyperkalemia was more frequent with RNA therapeutics (RR 2.80; 95% CI 1.30 to 6.04)”

    Reviewhypertension; versus control

    Hepatic Angiotensinogen-Lowering RNA Therapeutics for Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    AHA Scientific Sessions 2026 abstract

More on Hepatic angiotensinogen-lowering RNA therapeutics

Finerenone + SGLT2 inhibitors

upin humans1OR 1.6

1 study
  1. Finerenone + SGLT2 inhibitors raise the risk of hyperkalemia in humans (Chronic kidney disease; compared with SGLT2 inhibitor monotherapy) (OR 1.60, 95% CI 1.06–2.42).

    “combination therapy was associated with a higher risk of hyperkalemia (OR: 1.60; 95% CI: 1.06-2.42; p = 0.02; I 2 = 49%)”

    ReviewChronic kidney disease; compared with SGLT2 inhibitor monotherapyMedian follow-up: 12.5 monthsn = 8,196

    Finerenone Plus SGLT2 Inhibitors versus SGLT2 Inhibitor Monotherapy for Cardiorenal Outcomes: An Updated Meta-Analysis

    AHA Scientific Sessions 2026 abstract

More on Finerenone + SGLT2 inhibitors

Lorundrostat

upin humans1OR 7.64

1 study
  1. Lorundrostat raises the risk of hyperkalemia in humans (Hypertension; compared with placebo) (OR 7.64 [1.40-41.78]).

    “Significant hyperkalemia was observed with lorundrostat 100mg (OR 7.64 [1.40-41.78])”

    ReviewHypertension; compared with placebo100 mg

    Comparative Renal Safety and Efficacy of Baxdrostat vs Lorundrostat in Hypertensive Patients: A Systematic Review and Network Meta-Analysis

    AHA Scientific Sessions 2026 abstract

More on Lorundrostat

In-hospital mortality

upin humans1OR 2.63

1 study
  1. Hyperkalemia is associated with in-hospital mortality in humans (acute decompensated heart failure; K+ >5.5 mmol/L) (OR 2.63).

    “Independent risk factors were diabetes (OR 1.81), NYHA III–IV (OR 1.97), MLHFQ ≥41 (OR 2.09), atrial fibrillation (OR 2.29), hyperkalaemia (K+>5.5 mmol/L; OR 2.63)”

    Humansacute decompensated heart failure; K+ >5.5 mmol/Lin-hospitaln = 1,588

    Four-pillar era mortality prediction in acute decompensated heart failure: the ICARUS score

    ESC Congress 2026 abstract

Zilebesiran

upin humans1RR 3.24

1 study
  1. Zilebesiran raises the risk of hyperkalemia in humans (RR 3.24; 95% CI 1.40 to 7.49; p < 0.01).

    “zilebesiran was associated with a significantly higher risk of hyperkalaemia (RR 3.24; 95% CI 1.40 to 7.49; p < 0.01)”

    Review

    Efficacy and safety of zilebesiran for inadequately controlled hypertension: a systematic review and meta-analysis

    ESC Congress 2026 abstract

More on Zilebesiran

Nonsteroidal mineralocorticoid receptor antagonists

upin humans1

1 study
  1. Nonsteroidal mineralocorticoid receptor antagonists raise the risk of hyperkalemia in humans (versus placebo).

    “Safety analyses showed higher risks of hyperkalemia with nsMRAs and genital infections with SGLT2is than with placebo.”

    Human trialversus placebo

    Efficacy and safety of GLP-1RAs, SGLT2is, and nsMRAs for cardiovascular and renal outcomes in T2DM with CKD: a systematic review and network meta-analysis

    Frontiers in endocrinology

More on Nonsteroidal mineralocorticoid receptor antagonists

Salt substitute

upin humans1

1 study
  1. Salt substitute raises the risk of hyperkalemia in humans.

    “salt substitute increased mean serum potassium and led to more frequent biochemical hyperkalemia”

    Human trial2 years

    Salt substitution and salt-supply restriction for lowering blood pressure in elderly care facilities: a cluster-randomized trial

    Nature medicine

More on Salt substitute

All 18

Trial sponsors

Funding

1 grant since 2026

Japan Society for the Promotion of Science¥3.5M

How this record changed

  1. Summary written from the findings.

Latest

Dec 2025: 2Jan 2026: 13Feb 2026: 11Mar 2026: 10Apr 2026: 1May 2026: 3Jun 2026: 0Jul 2026: 4Aug 2026: 5Sep 2026: 9Oct 2026: 26Nov 2026: 32116 papers in 12 months

See all 152 papers on hyperkalemia